Drug details
Toujeo (insulin glargine injection for subcutaneous use)
type of Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins
Toujeo (insulin glargine) Injection is along-acting insulin indicated to improve glycemic control in adults with diabetes mellitus.
This drug may have the following side effects:
- allergic reactions
- itching
- rash
- upper respiratory tract infection
- weight gain
- low blood sugar (hypoglycemia)
- injection site reactions
- cold symptoms
- body fat redistribution (lipodystrophy)
- swelling of extremities, and
The following drugs are related to Toujeo, either as a replacement or used together:
- Actos (pioglitazone hydrochloride)
- Avandia (rosiglitazone maleate)
- Farxiga (dapagliflozin film-coated tablets)
- Zegalogue (dasiglucagon injection)
- Lantidra (donislecel-jujn allogeneic pancreatic islet cellular)
- Jardiance (empagliflozin tablets)
- Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets)
- Glyset (miglitol)
- Semglee (insulin glargine injection)
- Toujeo U 300 (insulin glargine injection for subcutaneous use)
- Rezvoglar (insulin glargine-aglr injection)
- Novolin N (insulin isophane)
- Lyumjev (insulin lispro-aabc injection)
- Janumet (sitagliptin metformin hcl)
- Janumet XR (sitagliptin and metformin hcl)
- Kombiglyze XR (saxagliptin and metformin hcl extended-release)
- Tradjenta (linagliptin)
- Victoza (liraglutide [rdna] injection)
- Myalept (metreleptin for injection)
- Mounjaro (tirzepatide injection)
- Tzield (teplizumab-mzwv injection, for intravenous use)